UM
FATE icon

UniSuper Management’s Fate Therapeutics FATE Stock Holding History

UniSuper Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,350
Closed -$27.5K – 1008
2023
Q4 		$27.5K Hold
7,350
– – ﹤0.01% 745
2023
Q3 		$15.6K Hold
7,350
– – ﹤0.01% 742
2023
Q2 		$35K Buy
+7,350
New +$40.6K ﹤0.01% 727

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UniSuper Management's FATE Position: Q1 2024 in Review

UniSuper Management sold out of Fate Therapeutics (FATE) in Q1 2024, closing a stake of 7,350 shares — an estimated $27.5K sold.

UniSuper Management first reported a position in FATE in Q2 2023 and held it in 3 quarters. The position peaked at $35K in Q2 2023. 167 funds tracked by Wall St. Rank hold FATE as of Q1 2024.

  • UniSuper Management reported no remaining Fate Therapeutics position as of Q1 2024 after selling out during the quarter.
  • UniSuper Management sold 7,350 Fate Therapeutics shares in Q1 2024, an estimated $27.5K.
  • UniSuper Management first reported a position in Fate Therapeutics in Q2 2023 and held it in 3 quarters.
  • UniSuper Management's Fate Therapeutics position peaked at $35K in Q2 2023.
  • 167 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2024.

Based on UniSuper Management's 13F filing for Q1 2024, filed 13 May 2024.